Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases

US10507250B2 · kind B2 · utility

Assignee

• INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN · TW

Inventors

• Ming Li · Hong Kong, CN
• Chyng-Yann Shiue · East Setauket, US
• Han-Chih Chang · Taoyuan, TW
• Chun-Fang Feng · Taoyuan, TW

Key dates

• Filing date: Sep 8, 2017
• Grant date: Dec 17, 2019
• Expiry date: Sep 17, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G06T2207/30016
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Method provided for labeling a nuclear medicine for imaging tracing, comprising a labeling precursor of the HDAC inhibitor BNL-26 (C22H23N3O) and the derivatives that are separated into two classes. The first class comprises a BNL-26 (C22H23N3O) and derivatives BNL-26a (C21H21N3O), BNL-26b (C22H22N2O), and other compounds of the labeling precursors which are categorized into two parts, the first part includes BNL-26-CH2CH2OTs (C31H33N3O4S), BNL-26a-CH2CH2OTs (C30H31N3O4S), and BNL-26b-CH2CH2OTs (C31H32N2O4S), which provides labeling precursor through —CH2CH2OTs structure, and the second part includes pre-BNL-26 (C28H34N3O3B), pre-BNL-26a (C27H32N3O3B), pre-BNL-26b (C28H33N2O3B), which provides labeling precursor through 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl structure. The second class includes BNL-26 (C22H23N3O) indole/indoline, which provides a series of derivative labeling precursors derived from a secondary amide bond.